Recent Therapeutic Advances in the Treatment of Colorectal Cancer

被引:165
作者
Ciombor, Kristen K. [1 ]
Wu, Christina [1 ]
Goldberg, Richard M. [1 ]
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源
ANNUAL REVIEW OF MEDICINE, VOL 66 | 2015年 / 66卷
关键词
biologics; aflibercept; regorafenib; RAS; aspirin; immunotherapy; PHASE-III TRIAL; MULTICENTER RANDOMIZED-TRIAL; BRAF MUTATION STATUS; 1ST-LINE TREATMENT; INFUSIONAL FLUOROURACIL; COLON-CANCER; ASPIRIN USE; PLUS IRINOTECAN; PIK3CA MUTATION; RAS MUTATIONS;
D O I
10.1146/annurev-med-051513-102539
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Metastatic colorectal cancer is a prevalent disease for which novel targeted therapies and biologically based combinations are under development. Cytotoxic chemotherapy doublets (FOLFOX, FOLFIRI) and triplets (FOLFOXIRI) in combination with biologics are standard regimens, and efforts are ongoing to delineate the optimal sequence for each patient based on unique underlying tumor biology. Molecular profiling of metastatic colorectal cancer (including mutational analysis for KRAS, NRAS, BRAF, PIK3CA, and others) has become increasingly important for identification of prognostic and predictive biomarkers, as well as for insights into the biology that drives the tumor. Large comprehensive analyses such as that of The Cancer Genome Atlas have provided important clues into carcinogenesis and discerned potentially druggable targets for metastatic colorectal cancer. Novel therapeutic agents currently under investigation for subtypes of this disease include immunotherapies such as anti-programmed cell death receptor antibody, cancer stem cell inhibitors, targeted combinations such as BRAF and PI3K inhibitors, and the anti-RAS reovirus Reolysin (R).
引用
收藏
页码:83 / 95
页数:13
相关论文
共 62 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]  
[Anonymous], 2010, CANCER
[3]  
[Anonymous], EP END RES PROGR SEE
[4]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[5]   Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A [J].
Bos, C. L. ;
Kodach, L. L. ;
van den Brink, G. R. ;
Diks, S. H. ;
van Santen, M. M. ;
Richel, D. J. ;
Peppelenbosch, M. P. ;
Hardwick, J. C. H. .
ONCOGENE, 2006, 25 (49) :6447-6456
[6]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[7]   Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial [J].
Burn, John ;
Gerdes, Anne-Marie ;
Macrae, Finlay ;
Mecklin, Jukka-Pekka ;
Moeslein, Gabriela ;
Olschwang, Sylviane ;
Eccles, Diane ;
Evans, D. Gareth ;
Maher, Eamonn R. ;
Bertario, Lucio ;
Bisgaard, Marie-Luise ;
Dunlop, Malcolm G. ;
Ho, Judy W. C. ;
Hodgson, Shirley V. ;
Lindblom, Annika ;
Lubinski, Jan ;
Morrison, Patrick J. ;
Murday, Victoria ;
Ramesar, Raj ;
Side, Lucy ;
Scott, Rodney J. ;
Thomas, Huw J. W. ;
Vasen, Hans F. ;
Barker, Gail ;
Crawford, Gillian ;
Elliott, Faye ;
Movahedi, Mohammad ;
Pylvanainen, Kirsi ;
Wijnen, Juul T. ;
Fodde, Riccardo ;
Lynch, Henry T. ;
Mathers, John C. ;
Bishop, D. Timothy .
LANCET, 2011, 378 (9809) :2081-2087
[8]   Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer [J].
Coffee, Erin M. ;
Faber, Anthony C. ;
Roper, Jatin ;
Sinnamon, Mark J. ;
Goel, Gautam ;
Keung, Lily ;
Wang, Wei Vivian ;
Vecchione, Loredana ;
de Vriendt, Veerle ;
Weinstein, Barbara J. ;
Bronson, Roderick T. ;
Tejpar, Sabine ;
Xavier, Ramnik J. ;
Engelman, Jeffrey A. ;
Martin, Eric S. ;
Hung, Kenneth E. .
CLINICAL CANCER RESEARCH, 2013, 19 (10) :2688-2698
[9]   Reovirus therapy of tumors with activated Ras pathway [J].
Coffey, MC ;
Strong, JE ;
Forsyth, PA ;
Lee, PWK .
SCIENCE, 1998, 282 (5392) :1332-1334
[10]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947